Xarelto Drugmakers Trying to Replace Safer Stroke Prevention Medications

Xarelto drugmakers have commenced new clinical trials and campaigns to convince the FDA to expand approvals of their anti-coagulant drug for stroke patients, potentially putting hundreds of thousands of additional lives at risk of its dangerous side effects. Bayer and Johnson & Johnson’s new 7,000-patient trial will test the effectiveness of Xarelto versus traditional stroke prevention medications, such as aspirin. Critics of the drug question the safety of prescribing Xarelto to stroke patients—or to any patient, for that matter—due to potentially fatal, non-reversible bleeding events. For these drug safety advocates, it seems counterintuitive to prescribe already at-risk patients these dangerous drugs when they are presently taking safer alternative medications.

Real Time Analytics